German pharmaceutical R&D stagnates as clinical development lags research
XLV•Germany’s pharmaceutical R&D remains stagnant: life sciences equity investment fell 15%, industry-sponsored Phase I trials declined 10%, and gene and cell therapy trials dropped 39%.
1. Investment and trials decline
The October 20 PROUD update said Germany’s pharmaceutical research and development remains stagnant despite government efforts to strengthen the sector. Life sciences equity investment fell 15%, industry-sponsored Phase I trials declined 10%, and gene and cell therapy trials dropped 39%.
2. Clinical development lags
Germany’s share of global clinical trial patient recruitment stagnated at about 3%, despite continued strength in basic medical research. Experts’ rating of Germany’s overall attractiveness fell to 5.65 from 5.80 out of 10, marking a second consecutive annual decline.
